-
Views
-
Cite
Cite
Michelle Locke, Commentary on “Behavior of Visfatin in Nonobese Women Undergoing Liposuction: A Pilot Study”, Aesthetic Surgery Journal, Volume 30, Issue 5, September/October 2010, Pages 733–734, https://doi.org/10.1177/1090820X10381992
Close - Share Icon Share
Extract
In their article, “Behavior of Visfatin in Nonobese Women Undergoing Liposuction: A Pilot Study,” the authors investigate the change in serum visfatin levels in 33 women who underwent elective abdominal subcutaneous liposuction with an average volume of 4400 mL removed. They demonstrated a statistically-significant rise in visfatin levels, from an average of 51.9 ng/mL preoperatively to 76.3 ng/mL one month postoperatively.
The authors are to be commended for incorporating basic science research into their elective cosmetic surgical treatment. Over recent years, adipose tissue has been extensively investigated for its metabolic properties, along with its reservoir of mesenchymal stem cells. As well as storing and secreting lipid, adipose tissue has been found to be a highly secretory organ.1 Hormones secreted by adipose tissue include leptin and adiponectin, whereas adipose-derived cytokines (adipocytokines) include interleukin-6 (IL-6) and tumor necrosis factor α (TNFα). Visfatin is an adipose cell-derived protein that is so named because it is predominantly found in visceral fat. Upper body obesity is a well-recognized risk factor for disorders of insulin resistance, such as type 2 diabetes mellitus (T2DM). In this regard, it seems that visceral stores of adipose tissue are more harmful than subcutaneous adipose tissue.2 Therefore, treatments that affect the levels of various visceral fat secretions, such as visfatin, may have a more significant effect on the development of insulin resistance disorders than treatments that affect subcutaneous fat secretions.
